Ross Osborne's questions to Elutia Inc (ELUT) leadership • Q2 2025
Question
Speaking for Ross Osborne, Matt Park of Cantor Fitzgerald asked about the outlook for gross margin expansion and the clinical evidence strategy required for the FDA approval of the NXT 41X platform.
Answer
CFO Matt Ferguson stated that the company sees clear opportunities to expand gross margins through scaling Elupro production, growing the high-margin cardiovascular business, and improving efficiency in the SimpliDerm franchise. CEO Randy Mills added that the NXT 41X platform will follow the same combination device regulatory pathway as Elupro, which they are confident in navigating. He noted the staggered launch is a marketing strategy to build clinical data, not a regulatory necessity.